---
title: Etoricoxib + Serratiopeptidase
description: >-
  Etoricoxib + Serratiopeptidase is prescribed for the management of pain and
  inflammation associated with various musculoskeletal conditions, including:
is_banned: false
lastModified: '2025-09-22T17:22:09.185Z'
faqs:
  - q: >-
      What is the recommended dosage for Etoricoxib + Serratiopeptidase?**


      **A:**  The standard adult dose is 60mg etoricoxib + 10mg
      serratiopeptidase once daily, adjustable up to 90mg etoricoxib + 15mg
      serratiopeptidase based on patient response. Specific conditions like
      acute gout or post-operative dental pain may have different
      recommendations.  Not for use in children under 16. Dose adjustments are
      needed for patients with hepatic or renal impairment.
    a: >-
      A:**  The standard adult dose is 60mg etoricoxib + 10mg serratiopeptidase
      once daily, adjustable up to 90mg etoricoxib + 15mg serratiopeptidase
      based on patient response. Specific conditions like acute gout or
      post-operative dental pain may have different recommendations.  Not for
      use in children under 16. Dose adjustments are needed for patients with
      hepatic or renal impairment.
  - q: >-
      What are the main contraindications for this combination?**


      **A:** Key contraindications include hypersensitivity to either drug,
      aspirin or other NSAID allergy, active peptic ulcers/GI bleeding, severe
      heart, liver, or kidney failure, and the third trimester of pregnancy.
    a: >-
      A:** Key contraindications include hypersensitivity to either drug,
      aspirin or other NSAID allergy, active peptic ulcers/GI bleeding, severe
      heart, liver, or kidney failure, and the third trimester of pregnancy.
  - q: >-
      How does this combination work to reduce pain and inflammation?**


      **A:** Etoricoxib inhibits COX-2, decreasing prostaglandin production. 
      Serratiopeptidase breaks down inflammatory proteins at the site of injury.
      This combined action leads to pain and swelling reduction.
    a: >-
      A:** Etoricoxib inhibits COX-2, decreasing prostaglandin production. 
      Serratiopeptidase breaks down inflammatory proteins at the site of injury.
      This combined action leads to pain and swelling reduction.
  - q: >-
      Are there any significant drug interactions I should be aware of?**


      **A:** Yes,  clinically relevant interactions can occur with
      anticoagulants (increased bleeding risk), antihypertensives (decreased
      effect), lithium (increased levels), methotrexate (increased toxicity),
      and rifampicin (decreased etoricoxib levels).
    a: >-
      A:** Yes,  clinically relevant interactions can occur with anticoagulants
      (increased bleeding risk), antihypertensives (decreased effect), lithium
      (increased levels), methotrexate (increased toxicity), and rifampicin
      (decreased etoricoxib levels).
  - q: >-
      Can this be prescribed to pregnant or breastfeeding women?**


      **A:**  No, it's generally not recommended, especially during the third
      trimester of pregnancy and during breastfeeding, due to potential risks to
      the fetus/infant.
    a: >-
      A:**  No, it's generally not recommended, especially during the third
      trimester of pregnancy and during breastfeeding, due to potential risks to
      the fetus/infant.
  - q: >-
      What are the most common side effects patients might experience?**


      **A:** Common side effects include gastrointestinal issues (diarrhea,
      stomach pain, indigestion, flatulence), fluid retention (swelling in hands
      and feet), and flu-like symptoms.
    a: >-
      A:** Common side effects include gastrointestinal issues (diarrhea,
      stomach pain, indigestion, flatulence), fluid retention (swelling in hands
      and feet), and flu-like symptoms.
  - q: >-
      What monitoring parameters are important when prescribing this
      medication?**


      **A:** It's crucial to monitor blood pressure, renal and liver function
      tests, and look for any signs of gastrointestinal bleeding.
    a: >-
      A:** It's crucial to monitor blood pressure, renal and liver function
      tests, and look for any signs of gastrointestinal bleeding.
  - q: >-
      Are there any specific dietary or lifestyle recommendations for patients
      taking this medication?**


      **A:**  Patients should avoid alcohol and quit smoking. A healthy diet and
      regular exercise are also important, especially in the context of managing
      chronic conditions like arthritis.
    a: >-
      A:**  Patients should avoid alcohol and quit smoking. A healthy diet and
      regular exercise are also important, especially in the context of managing
      chronic conditions like arthritis.
  - q: >-
      What should I do if a patient experiences a serious side effect?**


      **A:** Discontinue the medication immediately and provide appropriate
      supportive care.  Specific management depends on the nature of the side
      effect (e.g., managing allergic reactions, GI bleeding, etc.). Promptly
      consult with a specialist if needed.
    a: >-
      A:** Discontinue the medication immediately and provide appropriate
      supportive care.  Specific management depends on the nature of the side
      effect (e.g., managing allergic reactions, GI bleeding, etc.). Promptly
      consult with a specialist if needed.
---
## **Usage**

Etoricoxib + Serratiopeptidase is prescribed for the management of pain and inflammation associated with various musculoskeletal conditions, including:

* Osteoarthritis
* Rheumatoid arthritis
* Ankylosing spondylitis
* Acute pain conditions (e.g., post-operative pain, dental pain, back pain, dysmenorrhea)

**Pharmacological Classification:**

* Non-steroidal anti-inflammatory drug (NSAID) - Etoricoxib
* Proteolytic enzyme - Serratiopeptidase

**Mechanism of Action:**

Etoricoxib selectively inhibits cyclooxygenase-2 (COX-2), an enzyme responsible for producing prostaglandins, which mediate pain, inflammation, and fever. Serratiopeptidase breaks down inflammatory proteins, reduces swelling, and promotes tissue repair.  The combination of these two agents provides synergistic analgesic and anti-inflammatory effects.


## **Alternate Names**

There are no officially recognized alternate names for the combination product.  However, it's important to recognize that this refers to the fixed-dose combination of the two drugs. Individually, etoricoxib may be known as Arcoxia in some regions, and serratiopeptidase is sometimes referred to as serrapeptase.


## **How It Works**

**Pharmacodynamics:**  Etoricoxib exerts its analgesic and anti-inflammatory effects by selectively inhibiting COX-2, reducing prostaglandin synthesis. Serratiopeptidase reduces swelling and facilitates tissue repair by breaking down inflammatory proteins like bradykinin and fibrin.

**Pharmacokinetics:**

* **Etoricoxib:** Well absorbed orally, extensively metabolized primarily by CYP3A4, and excreted mainly via the kidneys.
* **Serratiopeptidase:** Absorbed in the intestines.  The elimination mechanism is not fully understood.

**Mode of Action:** Etoricoxib binds to and inhibits COX-2. Serratiopeptidase breaks down proteins involved in inflammation, including fibrin and bradykinin.

**Elimination Pathways:** Etoricoxib is primarily eliminated through renal excretion after hepatic metabolism by CYP enzymes, especially CYP3A4.  The elimination pathway of serratiopeptidase is not well-defined.


## **Dosage**

### **Standard Dosage**

#### **Adults:**

The usual recommended dose is 60 mg etoricoxib + 10 mg serratiopeptidase once daily. The dose can be increased up to a maximum of 90 mg etoricoxib + 15 mg serratiopeptidase once daily in some cases, based on individual response and tolerability. For acute gouty arthritis, 120 mg etoricoxib may be used once daily for a maximum of 8 days. For acute postoperative dental pain, 90 mg etoricoxib daily, limited to 3 days, is recommended.


#### **Children:**

Etoricoxib + Serratiopeptidase is not recommended for children under 16 years of age.



#### **Special Cases:**

* **Elderly Patients:** No dosage adjustment is typically necessary but caution is advised due to the increased risk of adverse effects. Close monitoring for gastrointestinal, renal, and cardiovascular events is recommended.

* **Patients with Renal Impairment:** Dose adjustment is necessary for patients with moderate to severe renal impairment.  In those with advanced renal disease (creatinine clearance < 30 mL/min), the combination is not recommended.

* **Patients with Hepatic Dysfunction:** Patients with mild hepatic impairment may require a lower dose (up to 60 mg etoricoxib daily). Those with moderate hepatic impairment may need an even further reduction (up to 30 mg etoricoxib daily).  The combination is contraindicated in severe hepatic impairment.

* **Patients with Comorbid Conditions:** Caution is advised in patients with a history of cardiovascular disease, hypertension, diabetes, fluid retention, stomach ulcers or bleeding.  Close monitoring is necessary.


### **Clinical Use Cases**

The dosages mentioned in the standard dosage section are typically applicable in these clinical settings, adjusted based on individual patient response and disease severity:

* **Intubation:**  Not specifically indicated for use during intubation.
* **Surgical Procedures:** Can be used for postoperative pain management, particularly after dental surgery (90mg etoricoxib maximum for 3 days).
* **Mechanical Ventilation:** Not specifically indicated for use during mechanical ventilation.
* **Intensive Care Unit (ICU) Use:**  Can be used for pain management under careful monitoring, with dose adjustments according to renal and hepatic function.
* **Emergency Situations:**  Not generally recommended in most emergency situations, as other analgesics might be preferred.



### **Dosage Adjustments**

Dose modifications are based on patient-specific factors such as:

* Renal/hepatic dysfunction (as detailed above)
* Age (elderly patients)
* Concomitant medications


## **Side Effects**

### **Common Side Effects:**

* Diarrhea
* Stomach pain
* Indigestion
* Flatulence
* Swelling of hands and feet
* Flu-like symptoms
* Dizziness
* Headache


### **Rare but Serious Side Effects:**

* Myocardial infarction
* Stroke
* Gastrointestinal bleeding
* Severe allergic reactions (e.g., anaphylaxis, angioedema)
* Liver damage
* Renal impairment



### **Long-Term Effects:**

Chronic complications from prolonged use can include cardiovascular risks like myocardial infarction and stroke, especially at higher doses.  Gastrointestinal issues, renal impairment, and hypertension are also possible.



### **Adverse Drug Reactions (ADR):**

Clinically significant ADRs requiring immediate intervention include severe allergic reactions, myocardial infarction, stroke, and gastrointestinal bleeding.


## **Contraindications**

* Hypersensitivity to etoricoxib, serratiopeptidase, or any component
* History of asthma, urticaria, or allergic reactions to aspirin or other NSAIDs
* Active peptic ulcer or gastrointestinal bleeding
* Severe heart failure
* Severe hepatic impairment
* Severe renal impairment
* Third trimester of pregnancy


## **Drug Interactions**

* **Anticoagulants (e.g., warfarin):** Increased risk of bleeding
* **Antihypertensives (e.g., ACE inhibitors, diuretics):** Reduced antihypertensive effect
* **Lithium:** Increased lithium levels
* **Methotrexate:** Increased methotrexate toxicity
* **Rifampicin:** Decreased etoricoxib levels
* **Other NSAIDs:** Increased risk of gastrointestinal side effects


## **Pregnancy and Breastfeeding**

Etoricoxib + Serratiopeptidase is not recommended during pregnancy, especially in the third trimester, and during breastfeeding. Consult a physician for alternative options.



## **Drug Profile Summary**

* **Mechanism of Action:** Etoricoxib: COX-2 inhibitor. Serratiopeptidase: Proteolytic enzyme.
* **Side Effects:** Diarrhea, stomach pain, GI upset, fluid retention, cardiovascular risks.
* **Contraindications:** Hypersensitivity, severe hepatic/renal impairment, active GI bleeding.
* **Drug Interactions:** Anticoagulants, antihypertensives, lithium, methotrexate.
* **Pregnancy & Breastfeeding:** Not recommended.
* **Dosage:** Adults: Typically 60mg etoricoxib/10mg serratiopeptidase once daily, adjustable.  Not for use in children under 16.
* **Monitoring Parameters:** Blood pressure, renal and liver function tests, signs of GI bleeding.


## **Popular Combinations**

While the combination of etoricoxib and serratiopeptidase is itself a popular fixed-dose combination in some regions, additional drugs are not typically added to this mix. The rationale for combining etoricoxib and serratiopeptidase is their synergistic analgesic and anti-inflammatory actions. 


## **Precautions**

* **General Precautions:** Pre-screening for allergies, renal/hepatic dysfunction, cardiovascular disease, and gastrointestinal disorders is essential.

* **Specific Populations:** As discussed in earlier sections, careful consideration is needed for pregnant women, breastfeeding mothers, children, and the elderly.

* **Lifestyle Considerations:** Alcohol should be avoided, as it can increase the risk of gastrointestinal side effects. Smoking cessation is strongly advised, as it can exacerbate cardiovascular risks.



## **FAQs (Frequently Asked Questions)**

### **Q1: What is the recommended dosage for Etoricoxib + Serratiopeptidase?**

**A:**  The standard adult dose is 60mg etoricoxib + 10mg serratiopeptidase once daily, adjustable up to 90mg etoricoxib + 15mg serratiopeptidase based on patient response. Specific conditions like acute gout or post-operative dental pain may have different recommendations.  Not for use in children under 16. Dose adjustments are needed for patients with hepatic or renal impairment.


### **Q2: What are the main contraindications for this combination?**

**A:** Key contraindications include hypersensitivity to either drug, aspirin or other NSAID allergy, active peptic ulcers/GI bleeding, severe heart, liver, or kidney failure, and the third trimester of pregnancy.

### **Q3:  How does this combination work to reduce pain and inflammation?**

**A:** Etoricoxib inhibits COX-2, decreasing prostaglandin production.  Serratiopeptidase breaks down inflammatory proteins at the site of injury. This combined action leads to pain and swelling reduction.

### **Q4:  Are there any significant drug interactions I should be aware of?**

**A:** Yes,  clinically relevant interactions can occur with anticoagulants (increased bleeding risk), antihypertensives (decreased effect), lithium (increased levels), methotrexate (increased toxicity), and rifampicin (decreased etoricoxib levels).

### **Q5: Can this be prescribed to pregnant or breastfeeding women?**

**A:**  No, it's generally not recommended, especially during the third trimester of pregnancy and during breastfeeding, due to potential risks to the fetus/infant.

### **Q6: What are the most common side effects patients might experience?**

**A:** Common side effects include gastrointestinal issues (diarrhea, stomach pain, indigestion, flatulence), fluid retention (swelling in hands and feet), and flu-like symptoms.

### **Q7: What monitoring parameters are important when prescribing this medication?**

**A:** It's crucial to monitor blood pressure, renal and liver function tests, and look for any signs of gastrointestinal bleeding.

### **Q8: Are there any specific dietary or lifestyle recommendations for patients taking this medication?**

**A:**  Patients should avoid alcohol and quit smoking. A healthy diet and regular exercise are also important, especially in the context of managing chronic conditions like arthritis.


### **Q9:  What should I do if a patient experiences a serious side effect?**

**A:** Discontinue the medication immediately and provide appropriate supportive care.  Specific management depends on the nature of the side effect (e.g., managing allergic reactions, GI bleeding, etc.). Promptly consult with a specialist if needed.




